Table 2 Prevalence (95% Confidence Interval) of GFR Stages by MDRD and CKD-EPI equations, based on subjects with available serum creatinine and urine (N=1,098) in a randomly selected representative sample of the middle and older Irish population
GFR Stage % (95% CI) Prevalence estimates N=1098 | GFR Stage% (95% CI) Prevalence estimates N=1098 | |
|---|---|---|
MDRD | CKD-EPI | |
GFR1 | 19.8% (17.4%, 22.1%) | 34.4% (31.6%, 37.2%) |
GFR 2 | 65.4% (62.6%, 68.2%) | 53.8% (50.8%, 56.7%) |
GFR3A | 11.8% (9.9%, 13.7%) | 9.2% (7.5%, 10.9%) |
GFR3B | 2.7% (1.8%, 3.7%) | 2.3% (1.5%, 3.3%) |
GFR 4-5 | 0.36% (0.07%, 0.7%) | 0.36% (0.07%, 0.7%) |
Total eGFR<60 | 14.9% (12.8%, 17%) | 11.8% (9.9, 13.8) |
Population Estimate (Weighted) eGFR<60 | 15.7% (12.7%, 18.7%) | 11.6% (9.0%, 14.2%) |
POPULATION PREVALENCE ESTIMATES OF CKD | ||
CKD STAGES | MDRD | CKD EPI |
CKD Stage 1 | 2.7% (1.9%, 3.9%) | 3.8% (2.8%, 5.1%) |
CKD Stage 2 | 7.2% (5.7%, 8.9%) | 6.3% (4.9%, 7.9%) |
CKD Stage 3A | 11.8% (9.9%, 13.8%) | 9.2% (7.5%, 10.9%) |
CKD Stage 3B | 2.7% (1.8%, 3.7%) | 2.3% (1.5%, 3.3%) |
CKD Stage 4-5 | 0.36% (0.07%, 0.7%) | 0.36% (0.07%, 0.7%) |
Total | 24.8% (22.2%, 27.3%) | 21.9% (19.5%, 24.4%) |
Population Estimate CKD (Weighted) | 25.1% (21.5%, 28.6%) | 21.3% (18%, 24.6%) |